{
    "clinical_study": {
        "@rank": "4895", 
        "arm_group": [
            {
                "arm_group_label": "subjects with ALS", 
                "description": "subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy"
            }, 
            {
                "arm_group_label": "subjects without ALS", 
                "description": "subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy"
            }
        ], 
        "biospec_descr": {
            "textblock": "skin and adipose tissue"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of the project is to obtain skin and adipose tissue samples from patients with\n      ALS to develop new diagnostic and prognostic markers of the disease.  These samples will be\n      obtained when percutaneous endoscopic gastrostomy (PEG) is performed as part of their\n      standard of care.  Skin and adipose tissue samples will also be obtained from disease\n      control subjects who require a PEG as part of their standard of care."
        }, 
        "brief_title": "Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Amyotrophic Lateral Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Amyotrophic Lateral Sclerosis", 
                "Sclerosis", 
                "Motor Neuron Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  for ALS patients, subjects must be diagnosed with definite ALS according to the El\n             Escorial Critera (EEC)\n\n          -  all subjects must be diagnosed with a condition requiring PEG (percutaneous\n             endoscopic gastrostomy) tube insertion\n\n          -  subjects must be older than 18 years of age\n\n        Exclusion Criteria:\n\n          -  children 18 years old and younger"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients at the Carolinas Neuromuscular/ALS-MDA Center and patients at Carolinas Medical\n        Center."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948102", 
            "org_study_id": "CHS-Neurology_ALS_TDI_PEG"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Amyotrophic Lateral Sclerosis", 
            "motor neuron disease", 
            "biological markers", 
            "biomarkers"
        ], 
        "lastchanged_date": "September 18, 2013", 
        "location": {
            "contact": {
                "email": "cynthia.lary@carolinashealthcare.org", 
                "last_name": "Cynthia Lary", 
                "phone": "704-446-6063"
            }, 
            "contact_backup": {
                "email": "carissa.tonkins@carolinashealthcare.org", 
                "last_name": "Carissa Tonkins", 
                "phone": "704-446-0836"
            }, 
            "facility": {
                "address": {
                    "city": "Charlotte", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "28207"
                }, 
                "name": "Carolinas Medical Center - Dept of Neurology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples", 
        "overall_contact": {
            "email": "cynthia.lary@carolinashealthcare.org", 
            "last_name": "Cynthia Lary", 
            "phone": "704-446-6063"
        }, 
        "overall_contact_backup": {
            "email": "carissa.tonkins@carolinashealthcare.org", 
            "last_name": "Carissa Tonkins", 
            "phone": "704-446-0836"
        }, 
        "overall_official": {
            "affiliation": "Carolinas Medical Center - Dept of Gastroenterology", 
            "last_name": "Thomas Pacicco, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Abundance levels of the known messenger RNA transcriptome  of skin  and adipose tissue samples (measured by gene expression profiling)", 
                "safety_issue": "No", 
                "time_frame": "After tissue has been collected from study subjects.  Data will be analyzed at 1 year."
            }, 
            {
                "measure": "Changes in abundance of or post-translational modification of proteins (measured by proteomics)", 
                "safety_issue": "No", 
                "time_frame": "After tissue has been collected from study subjects.  Data will be analzyed at year 1 after primary outcome data has been reviewed and analyzed"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948102"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Carolinas Healthcare System", 
            "investigator_full_name": "Benjamin Brooks", 
            "investigator_title": "Director, Neuromuscular/ ALS-MDA Center and Neuromuscular/ ALS Research Laboratory", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Carolinas Healthcare System", 
        "sponsors": {
            "collaborator": {
                "agency": "ALSTDI (ALS Therapy Development Institute)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Benjamin Brooks", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2008", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}